The companies said earlier this month that their vaccine was safe and 95 percent effective in a late-stage trial.
The companies said earlier this month that their vaccine was safe and 95 percent effective in a late-stage trial.
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться